TERN
Closed
Terns Pharmaceuticals Inc
3.85
+0.12 (+3.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.73
Day's Range: 3.665 - 4.09
Send
sign up or login to leave a comment!
When Written:
11.75
Terns Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing innovative treatments for liver diseases. The company was founded in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals is committed to developing therapies that address significant unmet medical needs and improve the lives of patients with liver diseases.
The company's lead product candidate, TERN-101, is a farnesoid X receptor (FXR) agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) that can lead to cirrhosis and liver failure. TERN-101 is currently in Phase 2a clinical trials.
Terns Pharmaceuticals has also developed a pipeline of other product candidates for the treatment of liver diseases, including TERN-201 for the treatment of primary biliary cholangitis (PBC) and TERN-501 for the treatment of NASH and other liver diseases.
The company has partnerships with several leading pharmaceutical companies, including Eli Lilly and Company, Merck & Co., and Astellas Pharma Inc., to develop and commercialize its product candidates.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate, TERN-101, is a farnesoid X receptor (FXR) agonist that is being developed for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) that can lead to cirrhosis and liver failure. TERN-101 is currently in Phase 2a clinical trials.
Terns Pharmaceuticals has also developed a pipeline of other product candidates for the treatment of liver diseases, including TERN-201 for the treatment of primary biliary cholangitis (PBC) and TERN-501 for the treatment of NASH and other liver diseases.
The company has partnerships with several leading pharmaceutical companies, including Eli Lilly and Company, Merck & Co., and Astellas Pharma Inc., to develop and commercialize its product candidates.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








